scholarly journals The Impact of HLA-Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the JSHCT HLA Working Group

2014 ◽  
Vol 20 (2) ◽  
pp. S57
Author(s):  
Junya Kanda ◽  
Yoshinobu Maeda ◽  
Kazuteru Ohashi ◽  
Takahiro Fukuda ◽  
Koichi Miyamura ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Retrospective Analysis ◽  
Marrow Transplantation ◽  
Working Group ◽  
Unrelated Bone Marrow Transplantation ◽  
The Impact

Mismatching at HLA-DPB1 Is Not Associated with Survival in Patients with Acquired Aplastic Anemia Who Receive Unrelated Bone Marrow Transplantation

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3005-3005
Author(s):  
Hiroshi Yagasaki ◽  
Seiji Kojima ◽  
Shunichi Kato ◽  
Koji Kato ◽  
Hiromasa Yabe ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Survival Rate ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Acute Gvhd ◽  
Chronic Gvhd ◽  
Unrelated Bone Marrow Transplantation ◽  
Matched Group ◽  
The Impact

Abstract DNA typing for HLA-A, -B, -C, -DQB1 and -DRB1 determines outcome in patients with severe aplastic anemia (SAA) who receive unrelated bone marrow transplantation (U-BMT). Based on our previous study of 300 subjects, complete matched (10/10) donors are preferable, but 1-allele-mismatched (9/10) donors are also acceptable. Several studies have addressed the additive effects of HLA-DPB1 for patients with hematological malignancies. In recent reports, HLA-DPB1 mismatching decreased the incidence of relapse, but increased the incidence of acute GVHD. However, the impact of matching for HLA-DPB1 remains unknown in SAA patients. To explore the impact of HLA-DPB1 on the outcome, we analyzed outcomes in 169 recipients with SAA who received U-BMT from an HLA complete matched or 1-allele mismatched donor through the Japan Marrow Donor Program. Median patient age was 17 years (range: 1 to 64 years), and 102 males and 67 females were included. Among 169 pairs, 101 were matched for 10/10 alleles and 68 matched for 9/10 alleles. Although the overall survival was comparable between the groups (10/10 matched group; 75.2%, 9/10 matched group; 64.5%, p=0.633), the incidence of acute GVHD (II–IV) was significantly higher in the 9/10 matched group (15.3%) than in 10/10 matched group (32.2%) (p=0.012). Therefore the impact of HLA-DPB1 matching was analyzed independently in each group. In the 10/10 matched group, 30 of 101 pairs (30%) were matched for HLA-DPB1, whereas 71 pairs (70%) were mismatched for HLA-DPB1. In the 9/10 matched group, 21 of 68 pairs (30%) were matched for HLA-DPB1, whereas 47 pairs (70%) were mismatched for HLA-DPB1. In the 10/10 matched transplants, the survival rate was comparable between the HLA-DPB1 matched group (74.4%) and the HLA-DPB1 mismatched group (75.7%) (p=0.894). The incidence of acute GVHD (II-IV) was lower in the HLA-DPB1 matched group (8.0%) than in the HLA-DPB1 mismatched group (18.1%), but this difference was not significant (p=0.193). In 9/10 matched transplants, the survival rate was comparable between the HLA-DPB1 matched group (71.4%) and the HLA-DPB1 mismatched group (61.7%) (p=0.826). The incidence of acute GVHD (II-IV) was also lower in the HLADPB1 matched group (21.0%) than in the HLA-DPB1 mismatched group (37.2%), but this difference was not significant (p=0.169). The incidence of chronic GVHD and rejection rate were not associated with HLA-DPB1 matching. In conclusion, HLA-DPB1 matching is not essential for U-BMT recipients with SAA when 10/10 or 9/10 allele-matched donors are available.

Mycobacterium avium complex-associated peritonitis with CAPD after unrelated bone marrow transplantation

2014 ◽  
Vol 56 (6) ◽  
pp. e96-e98 ◽  
Author(s):  
Emiko Miyashita ◽  
Hisao Yoshida ◽  
Daisuke Mori ◽  
Natsuki Nakagawa ◽  
Takako Miyamura ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Mycobacterium Avium ◽  
Marrow Transplantation ◽  
Mycobacterium Avium Complex ◽  
Unrelated Bone Marrow Transplantation

Influence of HLA 1–3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation

2020 ◽  
Vol 99 (5) ◽  
pp. 1099-1110
Author(s):  
Koji Kawamura ◽  
Junya Kanda ◽  
Kazuteru Ohashi ◽  
Takahiro Fukuda ◽  
Koji Iwato ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Antithymocyte Globulin ◽  
Unrelated Bone Marrow Transplantation

Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood.

1997 ◽  
Vol 15 (2) ◽  
pp. 566-573 ◽  
Author(s):  
F Locatelli ◽  
C Niemeyer ◽  
E Angelucci ◽  
C Bender-Götze ◽  
S Burdach ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Myelodysplastic Syndrome ◽  
Marrow Transplantation ◽  
Working Group ◽  
Allogeneic Bone Marrow Transplantation ◽  
Chronic Myelomonocytic Leukemia ◽  
Allogeneic Bone ◽  
European Working ◽  
Myelomonocytic Leukemia

PURPOSE To evaluate the role of allogeneic bone marrow transplantation (BMT) in children with chronic myelomonocytic leukemia (CMML). PATIENTS AND METHODS Forty-three children with CMML given BMT and reported to the European Working Group on Myelodysplastic Syndrome in Childhood (EWOG-MDS) data base were evaluated. In 25 cases, the donor was a human leukocyte antigen (HLA)-identical or a one-antigen-disparate relative, in four cases a mismatched family donor, and in 14 a matched unrelated donor (MUD). Conditioning regimens consisted of total-body irradiation (TBI) and chemotherapy in 22 patients, whereas busulfan (Bu) with other cytotoxic drugs was used in the remaining patients. RESULTS Six of 43 patients (14%), five of whom received transplants from alternative donors, failed to engraft. There was a significant difference in the incidences of chronic graft-versus-host disease (GVHD) between children transplanted from compatible/one-antigen-mismatched relatives and from alternative donors (23% and 87%, respectively; P < .005). Probabilities of transplant-related mortality for children given BMT from HLA-identical/one-antigen-disparate relatives or from MUD/ mismatched relatives were 9% and 46%, respectively. The probability of relapse for the entire group was 58%, whereas the 5-year event-free survival (EFS) rate was 31%. The EFS rate for children given BMT from an HLA-identical sibling or one-antigen-disparate relative was 38%. In this latter group, patients who received Bu had a better EFS compared with those given TBI (62% v 11%, P < .01). CONCLUSION Children with CMML and an HLA-compatible relative should be transplanted as early as possible. Improvement of donor selection, GVHD prophylaxis, and supportive care are needed to ameliorate results of BMT from alternative donors.

Influence of donors/recipients HLA-C disparity in 110 unrelated bone marrow transplantation

1996 ◽  
Vol 47 (1-2) ◽  
pp. 80
Author(s):  
Z. Tatari ◽  
H. Espérou ◽  
C. Chastang ◽  
C. Fortier ◽  
J.C. Bensa ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Unrelated Bone Marrow Transplantation

High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation

1996 ◽  
Vol 47 (1-2) ◽  
pp. 82
Author(s):  
Jeannet Michel ◽  
Speiser Daniel ◽  
Rufer Nathalie ◽  
Grundschober Christophe ◽  
Gratwohl Alois ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
High Resolution ◽  
Marrow Transplantation ◽  
Hla Matching ◽  
Unrelated Bone Marrow Transplantation
Sign in / Sign up

Export Citation Format

Share Document